- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Further information:
- Topic in appraisal.
- Process:
- STA Standard
Provisional Schedule
- Committee meeting: 1:
- 04 March 2026
- Expected publication:
- 21 May 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- Bayer (larotrectinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Action Kidney Cancer
- Anthony Pilcher Bone Cancer Trust
- Asthma + Lung Foundation
- Black Health Agency for Equality
- Bob Champion Cancer Trust
- Bowel Cancer UK
- Breast Cancer Now
- Breast Cancer UK
- British Skin Foundation
- Butterfly Thyroid Cancer Trust
- Cancer 52
- Cancer Black Care
- Cancer Laryngectomee Trust
- Changing Faces
- Childhood Cancer Parents Alliance
- Children’s Cancer and Leukaemia Group
- Children with Cancer
- Genetic Alliance UK
- Get-A-Head
- GIST Cancer UK
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Kidney Cancer UK
- Kidney Care UK
- Kidney Research UK
- Let's Face It
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Mouth Cancer Foundation
- National Association of Laryngectomee Clubs
- National Kidney Federation
- NTRKers
- Orchid – Fighting Male Cancer
- OUTpatients
- Prostate Cancer UK
- Roy Castle Lung Cancer Foundation
- Sarcoma UK
- Solving Kid’s Cancer
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Swallows Head and Neck Cancer Support Group
- Teenage Cancer Trust
- Tenovus Cancer Care
- The Royal Marsden Cancer Charity
- Together for Short Lives
- UK Lung Cancer Coalition
- Women’s Health Concern
- Young Lives vs Cancer
- Professional groups
- Association of Anaesthetists
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- Association of Surgeons of Great Britain and Ireland
- British Association of Dermatologists
- British Association of Endocrine and Thyroid Surgeons
- British Association of Surgical Oncology
- British Association of Urological Surgeons
- British Dermatological Nursing Group
- British Geriatrics Society
- British Institute of Radiology
- British Oncology Pharmacy Association
- British Orthopaedic Association
- British Orthopaedic Oncology Society
- British Psychosocial Oncology Society
- British Sarcoma Group
- British Society for Dermatological Surgery
- British Society of Skeletal Radiologists
- British Society of Urogenital Radiology
- British Thoracic Oncology Group
- British Thoracic Society
- British Thyroid Association
- British Uro-oncology Group
- Cancer Research UK
- CCLG
- Lung Cancer Nursing UK
- Melanoma Focus
- Pelican Cancer Foundation
- Primary Care Dermatology Society
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatricians and Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Kidney Association
- UK Oncology Nursing Society
- UK Renal Pharmacy Group
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Against Breast Cancer
- Bone Cancer Research Trust
- Bone Research Society
- Breast Cancer Hope
- Breast Cancer Research Trust
- Cochrane Breast Cancer Group
- Cochrane Childhood Cancer Group
- Cochrane Lung Cancer Group
- Cochrane Prostatic Diseases Urologic Cancers Group
- Cochrane Skin Group
- Genomics England
- Institute of Cancer Research
- Melanoma Fund
- MRC Clinical Trials Unit
- National Institute for Health Research
- Oracle Cancer Trust
- Pro Cancer Research Fund
- Prostate Cancer Research Centre
- Research Institute for the Care of Older People
- Skin Cancer Research Fund
- Skin Treatment & Research Trust
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 August 2025 | Invitation to participate |
| 13 June 2025 - 10 July 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 13 June 2024 | Awaiting development |
| 13 June 2024 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual